Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2022-03-25 Audit Report / Informat…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
UCB_SA_Report_KAM FR.PDF
Audit Report / Information Classification · 98% confidence The document is explicitly titled "Rapport du commissaire à l'assemblée générale de UCB SA pour l'exercice clos le 31 décembre 2021" (Auditor's Report to the General Meeting of UCB SA for the year ended December 31, 2021). It contains the auditor's opinion ("Opinion sans réserve") on the annual accounts, details on key audit matters, and verification of the management report and compliance with Belgian corporate law. This content is characteristic of a formal Audit Report, which is distinct from the full Annual Report (10-K) or a simple announcement of a report (RPA). Given the focus on the auditor's findings and opinion on the annual accounts, the most appropriate classification is 'Audit Report / Information' (AR). The document is comprehensive, not just a short announcement. FY 2021
2022-03-25 French
2021 UCB Integrated Annual Report - NL.pdf
Annual Report Classification · 100% confidence The document is titled 'Geïntegreerd jaarverslag 2021' (Integrated Annual Report 2021) for UCB. It contains comprehensive financial statements, management reports, governance disclosures, and ESG performance data for the full fiscal year 2021. It is clearly the primary annual reporting document, not an announcement or a summary, and thus fits the definition of a 10-K (Annual Report). FY 2021
2022-03-25 Dutch
Proxy General Meeting 28 April 2022 - ENG - FINAL.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is explicitly titled "PROXY FOR THE GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON 28 APRIL 2022". It contains detailed instructions on how to appoint a proxy, the agenda items for both Ordinary and Extraordinary General Meetings (including resolutions on approving annual accounts, remuneration, director renewals, and capital changes), and voting options (FOR/AGAINST/ABSTAIN). This content is characteristic of proxy materials distributed to shareholders ahead of a shareholder meeting to solicit their votes. This aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI).
2022-03-25 English
2022- Rapport spécial du Conseil (art. 7-199) (23 fev 2022) - Signé.pdf
Capital/Financing Update Classification · 95% confidence The document is titled "RAPPORT SPÉCIAL DU CONSEIL D'ADMINISTRATION AUX ACTIONNAIRES concernant l'utilisation du capital autorisé et les objectifs poursuivis établi en application de l'article 7:199 du Code des sociétés et associations". This explicitly identifies it as a Special Report from the Board of Directors to Shareholders regarding the authorized capital, which is a specific corporate governance/financing document presented for shareholder approval at a general meeting (Extraordinary General Meeting mentioned). This type of report, detailing the framework and justification for capital structure decisions presented to shareholders, aligns best with the 'Capital/Financing Update' (CAP) or potentially 'Governance Information' (CGR) or 'Proxy Solicitation' (PSI) if it were a proxy statement. However, since it is a detailed report specifically about the authorization to increase capital, 'CAP' (Capital/Financing Update) is the most precise fit among the provided options, as it directly concerns the company's capital structure management and authorization renewal. It is not a standard 10-K, ER, or IR. It is a specific statutory report related to capital authorization, making CAP the strongest candidate.
2022-03-25 French
2022 - Bijzonder verslag van de Raad (art. 7-199) (23 feb 2022) - Getekend.pdf
Governance Information Classification · 95% confidence The document is titled "BIJZONDER VERSLAG VAN DE RAAD VAN BESTUUR AAN DE AANDEELHOUDERS over het gebruik en de nagestreefde doeleinden van het toegestane kapitaal opgesteld overeenkomstig artikel 7:199 van het Wetboek van vennootschappen en verenigingen" (Special Report of the Board of Directors to the Shareholders regarding the use and intended purposes of the authorized capital prepared pursuant to Article 7:199 of the Companies and Associations Code). This document explicitly discusses the renewal of the Board's authorization to increase capital within the framework of authorized capital, which is a proposal to be submitted to the Extraordinary General Shareholders' Meeting. This content directly relates to corporate governance, capital structure proposals, and shareholder voting matters, but the core purpose is to present the rationale and proposed changes for capital authorization powers, which is a key component of shareholder meeting materials or governance documents. Given the options: - It is not a standard Annual Report (10-K) or Interim Report (IR) as it focuses on authorization renewal, not periodic financial results. - It is not a simple Earnings Release (ER). - It is not a standard Proxy Solicitation (PSI) which usually solicits votes for director elections or routine matters, although it is related to a shareholder meeting. - It is a detailed report explaining the company's internal rules/governance regarding capital management and seeking authorization, which aligns closely with Governance Information (CGR). - However, the document is a "Bijzonder Verslag" (Special Report) presented in connection with a proposal to be voted on at an Extraordinary General Meeting (EGM) concerning the renewal of capital authorization powers. This type of document, detailing specific corporate powers and seeking shareholder approval for changes to the articles of association (as seen in Section III where Article 6 is proposed to be amended), often falls under Governance Information (CGR) or sometimes Proxy/Shareholder materials. Since it is a detailed report explaining the structure and proposed changes to the company's capital authorization framework, CGR is a strong fit. If it were solely the notice *for* the meeting, PSI might apply, but this is the substantive report accompanying the proposal. Considering the focus on the structure of authorized capital, the limits on the Board's power, and the proposed amendment to the Articles of Association (Article 6), this is fundamentally a report detailing corporate governance structure related to capital. Therefore, Governance Information (CGR) is the most appropriate classification.
2022-03-25 Dutch
2022 - Special Report by the Board (art. 7-199) (23 feb 2022) - signed.pdf
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled "SPECIAL REPORT BY THE BOARD OF DIRECTORS TO THE SHAREHOLDERS on the use and purpose of the authorized capital" and states it is "prepared in accordance with article 7:199 of the Belgian Code of Companies and Associations". This document details the proposal to renew the Board's powers to increase the share capital, which directly relates to the company's capital structure and financing authorization. This fits the description of a document concerning capital/financing activities, specifically related to shareholder authorization for capital changes. While it discusses capital, it is a formal report presented to shareholders regarding the authorization framework, not a general earnings release (ER) or a comprehensive interim/annual report (IR/10-K). It is a specific report detailing capital structure management, which aligns best with the 'Capital/Financing Update' (CAP) category, as it is a proposal/report seeking approval for future capital actions, or potentially a specialized report that might fall under 'Governance Information' (CGR) due to its statutory nature, but the core subject is capital authorization. Given the focus on renewing powers to issue shares, convertible bonds, or warrants, 'CAP' (Capital/Financing Update) is the most precise fit among the provided options for a statutory report detailing capital authorization limits and purposes.
2022-03-25 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.